Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06925152

COMFORT Trial: Complex Obstetric Management With Focused Regional Transversus Abdominis Plane Block

To assess the effect of intraoperative transversus abdominis plane (TAP) blocks on the amount of opioid pain medications expressed as morphine milliequivalents (MME) used postoperatively in patients who have undergone cesarean delivery (CD) in the setting of complex obstetric surgery (COS).

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–50 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 4

Primary location

Regional One Health

Memphis, Tennessee, 38103, United States

Location status: Recruiting

Location contact

Michael Vandillen, MD

CONTACT

[email protected]

314-619-1046

About this study

The Transversus Abdominis Plane (TAP) block is a regional anesthesia technique that targets the nerves innervating the abdominal wall, providing effective postoperative analgesia for patients undergoing various abdominal surgeries, including cesarean deliveries. The standard clinical practice for TAP blocks typically involves local anesthetics like bupivacaine, which, when administered in the appropriate plane, has been shown to reduce opioid consumption and improve pain management in the postoperative period.

Transversus abdominal plane (TAP) blocks, when administered intraoperatively, have demonstrated significant benefits in managing postoperative pain, especially in abdominal surgeries. Placing the TAP block during surgery provides early and prolonged analgesia, potentially reducing the need for postoperative opioids and improving recovery outcomes. A study completed in 2007 was one of the first to highlight the effectiveness of intraoperative TAP block placement in patients undergoing lower abdominal surgeries, showing a significant reduction in opioid consumption and better pain control. In the context of cesarean section, an intraoperative TAP block was shown to provide effective analgesia with a reduction in postoperative narcotic use. Similarly, a randomized trial in 2017 demonstrated that intraoperative TAP blocks significantly improved pain scores and reduced opioid consumption in patients undergoing colorectal surgeries. Furthermore, a study completed in 2014 found that performing TAP blocks intraoperatively for laparoscopic cholecystectomy patients resulted in lower visual analog scale (VAS) pain scores in the recovery room and reduced the incidence of postoperative nausea and vomiting. These findings underscore the advantages of intraoperative TAP block placement in enhancing postoperative analgesia across a variety of abdominal procedures.

Despite the widespread use of TAP blocks, there remains a gap in the literature regarding the effectiveness of bupivacaine TAP block use placed intraoperatively during more complex obstetric surgeries. Most existing studies focus on the use of TAP blocks for pain management after routine Pfannenstiel cesarean deliveries, with limited attention given to their role in cases involving higher-risk or more complicated obstetric situations, such as cesareans with significant intra-abdominal adhesions or other complications.

Although bupivacaine is commonly used in TAP blocks, its specific efficacy, optimal dosing, and potential benefits when placed intraoperatively in complex obstetric cases remain underexplored. The limited data in this area presents a critical gap in our understanding of how best to optimize pain management and improve surgical outcomes for women undergoing cesarean delivery, particularly in high-risk obstetric cases.

This blinded randomized controlled trial (RCT) seeks to address this gap by evaluating the effectiveness of intraoperative TAP blocks with bupivacaine during complex cesarean sections, focusing on the impact on postoperative analgesia and pain scores. By clarifying the role of bupivacaine in TAP blocks during complex obstetric surgery, this study aims to contribute valuable insights to the field of obstetric anesthesia and improve the perioperative experience for patients undergoing cesarean delivery.

Primary Objective: To assess the effect of intraoperative transversus abdominis plane (TAP) blocks on the amount of opioid pain medications expressed as morphine milliequivalents (MME) used postoperatively in patients who have undergone cesarean delivery (CD) in the setting of complex obstetric surgery (COS).

Primary Endpoint/Outcome: Pain medication requested, expressed as MMEs, between 24 and 48 hours after surgery.

Secondary Endpoint(s)/Outcome(s):

Total MME requested within first 24-hours post operatively Total MME requested within 48-hours post operatively Total MME at 1-week after surgery Functional assessment of activities of daily life (ADL) at 1-week post operatively Number of unplanned postoperative visits within 6-months of surgery Geographic region of patients needing complex obstetric surgery. Heat maps: diversity equity and inclusion (DEI) zip codes

Hypothesis: The investigators hypothesize that utilization of the TAP block will reduce MME requirements by 20% for patients who have undergone CD in the setting of COS.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patient has a history of a least one of the following:

  • Prior exploratory laparotomy
  • History of non-obstetric open intra-abdominal surgery
  • History of three or more prior cesarean deliveries
  • History of intra-abdominal or pelvic adhesive disease
  • History of abdominoplasty
  • History of abdominal re-exploration surgery

Exclusion criteria

  • Received general anesthesia
  • History of less than 3 cesarean deliveries if do not meet other inclusion criteria
  • History of chronic opioid use
  • History of substance abuse (i.e. alcohol, methamphetamine/amphetamine, abuse of prescription opioid medication, or heroin use)
  • History of chronic kidney disease
  • Allergies to bupivacaine or oral analgesics
  • Patient preference
  • Cesarean hysterectomy
  • Administration of ≥4mg morphine to epidural
  • Loss to follow-up

Treatment and study plan

Bupivicaine intervention arm

Drug

TAP blocks in intervention group will include 0.5% bupivacaine in 30mL solution of 15mL normal saline and 15mL bupivacaine

Placebo arm

Drug

Placebo group TAP block syringe will include 30mL normal saline

Primary outcomes

  1. Pain medication requested

    Time frame: Between 24 and 48 hours after surgery

    Total pain medication requested expressed in morphine milligram equivalents.

Secondary outcomes

  1. Total MME requested within first 24 hours postoperatively

    Time frame: 24 hours postoperatively

  2. Total MME requested within 48 hours postoperatively

    Time frame: 48 hours postoperatively

  3. Total MME at one week after surgery

    Time frame: One week postoperatively

  4. Functional assessment of activities of daily life (ADL) at one week postoperatively

    Time frame: One week postoperatively

  5. Number of unplanned postoperative visits within six months of surgery

    Time frame: Six months postoperatively

  6. Geographic region of patients needing complex obstetric surgery

    Time frame: 24 months - through the duration of the study

    Heat maps to evaluate the distribution of patients across different demographic categories based on race and age within certain zip codes

Study contacts

Contact information is provided by the study sponsor or research team.

Michael VanDillen Fellow physician, PI of study, MD

CONTACT

[email protected]

314-619-1046

Sponsors and collaborators

Lead sponsor

University of Tennessee

Other

Collaborators

  • Regional One Health

Registry information

Acronym: COMFORT

Important dates

Study start
2025
Primary completion
2028
Study completion
2028
First posted
Apr 13, 2025
Registry last updated
Mar 11, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.